Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee

  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  BioPharma  /  Insmed, in de gaten houden

BioPharma« Terug naar discussie overzicht

Insmed, in de gaten houden

Volgen
20.047 Posts
Pagina: «« 1 ... 842 843 844 845 846 ... 1003 »» | Laatste | Omlaag ↓
  2. [verwijderd] 12 juni 2006 21:13
    Monday , June 12, 2006 14:54 ET

    Tercica, Inc. (TRCA) filed a complaint in the U.S. District Court for the Eastern District of Virginia, Richmond division alleging Insmed Incorporated (INSM) violated the Lanham Act and related statutes relating to false advertising and unfair competition. This action was taken after the presiding Judge for the U.S. District Court for the Northern District of California, dismissed on June 9, 2006 Tercica’s complaint for the same violations on the basis that she could not exercise jurisdiction over Insmed, which is based in Virginia. Her ruling also indicated that the complaint should establish that the requisite false statements were disseminated to consumers of Increlex™, e.g., the physicians who purchase and prescribe Increlex, rather than solely to investors. Tercica’s re-filing adds new allegations of false and misleading advertising that Insmed disseminated specifically to pediatric endocrinologists.

  4. [verwijderd] 12 juni 2006 21:19
    quote:

    DieGroeneGigant schreef:

    Monday , June 12, 2006 14:54 ET

    Tercica, Inc. (TRCA) filed a complaint in the U.S. District Court for the Eastern District of Virginia, Richmond division alleging Insmed Incorporated (INSM) violated the Lanham Act and related statutes relating to false advertising and unfair competition. This action was taken after the presiding Judge for the U.S. District Court for the Northern District of California, dismissed on June 9, 2006 Tercica’s complaint for the same violations on the basis that she could not exercise jurisdiction over Insmed, which is based in Virginia. Her ruling also indicated that the complaint should establish that the requisite false statements were disseminated to consumers of Increlex™, e.g., the physicians who purchase and prescribe Increlex, rather than solely to investors. Tercica’s re-filing adds new allegations of false and misleading advertising that Insmed disseminated specifically to pediatric endocrinologists.


    hehreh... bij verkeerde loket gefiled..daarom dismissed en nu opnieuw ingediend...

    homestate van insm nu... heheheheheh
  18. [verwijderd] 12 juni 2006 22:06
    quote:

    crackedtooth schreef:

    [quote=DieGroeneGigant]
    Monday , June 12, 2006 14:54 ET

    Tercica, Inc. (TRCA) filed a complaint in the U.S. District Court for the Eastern District of Virginia, Richmond division alleging Insmed Incorporated (INSM) violated the Lanham Act and related statutes relating to false advertising and unfair competition. This action was taken after the presiding Judge for the U.S. District Court for the Northern District of California, dismissed on June 9, 2006 Tercica’s complaint for the same violations on the basis that she could not exercise jurisdiction over Insmed, which is based in Virginia. Her ruling also indicated that the complaint should establish that the requisite false statements were disseminated to consumers of Increlex™, e.g., the physicians who purchase and prescribe Increlex, rather than solely to investors. Tercica’s re-filing adds new allegations of false and misleading advertising that Insmed disseminated specifically to pediatric endocrinologists.


    [/quote]

    hehreh... bij verkeerde loket gefiled..daarom dismissed en nu opnieuw ingediend...

    homestate van insm nu... heheheheheh
    Vertragings tactiek.. Geen enkele, zelfs geen amerikaanse, advocaat is zo dom om een proces te willen starten bij het verkeerde gerecht.. achterlijke vertoning.
20.047 Posts
Pagina: «« 1 ... 842 843 844 845 846 ... 1003 »» | Laatste |Omhoog ↑

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
FASTNED 18,260 +1,56 +9,34%
Alfen N.V. 13,065 +1,00 +8,29%
AMG Critical Materials N.V. 16,250 +0,97 +6,35%
Air France-KLM 8,614 +0,46 +5,62%
AZERION 1,542 +0,06 +4,19%
JUST EAT TAKEAWAY 12,715 +0,50 +4,09%
ADYEN NV 1.329,600 +45,00 +3,50%
Basic-Fit 22,740 +0,66 +2,99%
Akzo Nobel 59,100 +1,66 +2,89%
Pharming 0,721 +0,02 +2,78%
Brunel 8,620 +0,23 +2,74%
ArcelorMittal 21,070 +0,56 +2,73%
Avantium 1,974 +0,05 +2,49%
SIGNIFY NV 21,440 +0,50 +2,39%
TomTom 4,962 +0,11 +2,22%
TKH 37,120 +0,80 +2,20%
BAM 3,714 +0,08 +2,15%
PostNL 1,220 +0,02 +2,09%
Philips Koninklijke 28,270 +0,57 +2,06%
RANDSTAD NV 43,420 +0,82 +1,92%
ALLFUNDS GROUP 5,355 +0,10 +1,90%
Aperam 24,420 +0,44 +1,83%
Galapagos 27,680 +0,46 +1,69%
BESI 113,050 +1,80 +1,62%
PROSUS 32,770 +0,52 +1,61%
ABN AMRO BANK N.V. 16,465 +0,25 +1,57%
Kendrion 12,100 +0,16 +1,34%
ING 16,502 +0,20 +1,25%
ASMI 573,800 +6,20 +1,09%
ASCX 1.196,71 +12,89 +1,09%
Nedap N.V. 57,400 +0,60 +1,06%
AMX 897,55 +9,00 +1,01%
SHELL PLC 30,700 +0,31 +1,00%
ASML 726,900 +7,00 +0,97%
Van Lanschot Kempen NV 41,900 +0,40 +0,96%
AALBERTS NV 34,300 +0,30 +0,88%
SBM Offshore 16,440 +0,14 +0,86%
IMCD 157,300 +1,30 +0,83%
Fugro 20,820 +0,16 +0,77%
EXOR NV 98,400 +0,75 +0,77%
Sligro 13,160 +0,10 +0,77%
Corbion 23,820 +0,18 +0,76%
INPOST 17,210 +0,13 +0,76%
Aegon 5,472 +0,04 +0,70%
AEX 901,85 +6,10 +0,68%
HEIJMANS KON 23,700 +0,15 +0,64%
Accsys 0,640 +0,00 +0,63%
Vopak 42,800 +0,24 +0,56%
Wolters Kluwer 158,500 +0,85 +0,54%
RENEWI 7,640 +0,04 +0,53%
CM.COM 6,500 +0,03 +0,46%
Arcadis 65,250 +0,30 +0,46%
Ahold Delhaize 31,120 +0,13 +0,42%
Eurocommercial Properties 25,500 +0,10 +0,39%
Sif Holding 12,620 +0,04 +0,32%
ForFarmers 3,200 +0,01 +0,31%
NSI 20,950 +0,05 +0,24%
Fagron 18,960 +0,04 +0,21%
ACOMO 17,400 +0,02 +0,12%
RELX 43,200 +0,02 +0,05%

Dalers

instrument koers absoluut verschil relatief verschil
NX FILTRATION 4,640 -0,10 -2,11%
DSM FIRMENICH AG 118,250 -2,15 -1,79%
EBUSCO HOLDING 0,798 -0,01 -1,66%
THEON INTERNAT 11,140 -0,18 -1,59%
UMG 23,020 -0,37 -1,58%
WDP 24,500 -0,24 -0,97%
Flow Traders 18,100 -0,16 -0,88%
Wereldhave 14,840 -0,10 -0,67%
Vastned 23,800 -0,15 -0,63%
Heineken 81,460 -0,50 -0,61%
JDE PEET'S 20,320 -0,12 -0,59%
OCI 26,730 -0,12 -0,45%
UNILEVER PLC 58,500 -0,24 -0,41%
KPN 3,721 -0,01 -0,27%
CTP 16,560 -0,02 -0,12%
B&S Group SA 4,605 0,00 -0,11%
ASR Nederland 43,440 -0,02 -0,05%
NN Group 44,670 -0,02 -0,04%
vlag naam koers verschil relatief verschil
AEX 901,88 +6,13 +0,68%
AEX GR 3.521,86 +21,52 +0,61%
Germany40^ 18.761,30 +128,19 +0,69%
FTSE 100 8.318,94 +40,50 +0,49%
EURO50 4.868,48 +20,37 +0,42%
US30^ 41.815,80 +192,20 +0,46%
Nasd100^ 19.593,90 +174,70 +0,90%
US500^ 5.670,12 +36,35 +0,65%
Japan225^ 36.760,60 +73,50 +0,20%
VD-NEW 15,27 +0,64 +4,40%
#/^ Index indications calculated real time, zie disclaimer